AI Article Synopsis
- The article assesses the impact of Brazil's "Health Has No Price" Program on access to antihypertensive medications during its first year.
- A study tracked antihypertensive pill distribution in 55,000 pharmacies from February 2010 to January 2012, comparing supply data before and after the program's initiation.
- Results indicated significant increases (32%-120%) in the supply of specific antihypertensive drugs, suggesting the program improved access, while other related medications saw minimal or negative changes.
Article Abstract
Purpose: This article aims to evaluate access to antihypertensive agents during the first year of the "Health Has No Price" Program (Saúde Não Tem Preço [SNTP]) in Brazil.
Methods: A longitudinal and observational study was performed based on the number of antihypertensive medications supplied in 55,000 private pharmacies distributed throughout the Brazilian territory during the period February 1, 2010, through January 31, 2012. The number of antihypertensive pills supplied in the first 12 months of the SNTP Program was compared with the number of pills supplied in the 12 months before its implementation.
Findings: Six antihypertensive medicines showed an increase between 32% and 120% in the number of pills supplied in the first year of the program. In this same period, the growth of the Brazilian pharmaceutical market was ~13%. Additionally, 11 medicines containing the same active ingredients as the antihypertensive agents in the SNTP Program, but at concentrations not available for free, were analyzed; it was found that none showed a change >8%, and 5 showed a reduction in the number of pills supplied after the implementation of the SNTP Program. The analysis of 7 fixed-dose combinations not available in the SNTP Program that were formulated with the same active ingredients showed a change below the annual percentage growth of the Brazilian pharmaceutical market.
Implications: The SNTP Program may have contributed to increased access to antihypertensive medicines in Brazil.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinthera.2014.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brazilian generics market change after Farmácia Popular program.
Rev Saude Publica
November 2019
Fundação Oswaldo Cruz . Escola Nacional de Saúde Pública Sergio Arouca . Departamento de Ciências Sociais . Rio de Janeiro , RJ , Brasil.
Objective: To evaluate trends in the use of generic and non-generic medicines to treat hypertension and diabetes under the Farmácia Popular Program (FP) and its impact on generic medicines sales volume and market share in the Brazilian pharmaceutical market.
Methods: This longitudinal, retrospective study used interrupted time series design to analyze changes in monthly sales volume and proportion of medicines sales (market share) for oral antidiabetic and antihypertensive medicines for generic versus non-generic products. Analyses were conducted in a combined dataset that aggregate monthly sales volumes from the Farmácia Popular program and from the QuintilesIMS™ (IQVIA) national market sales data from January 2007 to December 2012.
Access to medicines for diabetes treatment in Brazil: evaluation of "health has no price" program.
Diabetol Metab Syndr
May 2016
Programa de Pós-graduação stricto sensu em Ciências Farmacêuticas, Universidade de Sorocaba, Rod Raposo Tavares, Km 92,5, Sorocaba, SP 18023-000 Brazil.
Background: In 2011, private pharmacies associated to the Brazilian Ministry of Health provided patients with two types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (5 mg glibenclamide and 500 and 850 mg metformin) free of charge. The aim was to evaluate the impact of the "Health Has No Price" Program [Saúde Não Tem Preço (SNTP)] for access to diabetes treatment medicines in Brazil.
Methods: This longitudinal and observational study is based on the number of units of oral hypoglycemic agents, insulin and insulin analogues supplied in 55,000 private pharmacies from February 1, 2010 to January 31, 2012.
Access to antihypertensive agents in Brazil: evaluation of the "health has no price" program.
Clin Ther
August 2014
Graduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Sao Paulo State, Brazil. Electronic address:
Article Synopsis
- The article assesses the impact of Brazil's "Health Has No Price" Program on access to antihypertensive medications during its first year.
- A study tracked antihypertensive pill distribution in 55,000 pharmacies from February 2010 to January 2012, comparing supply data before and after the program's initiation.
- Results indicated significant increases (32%-120%) in the supply of specific antihypertensive drugs, suggesting the program improved access, while other related medications saw minimal or negative changes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!